Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012065133 - IMMUNOMODULATORY METHODS AND SYSTEMS FOR TREATMENT AND/OR PREVENTION OF ANEURYSMS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

WHAT IS CLAIMED IS

1. A method to treat and/or prevent an aneurysm and/or a condition associated thereto in an individual, the method comprising

administering to the individual an effective amount of an immunogenic fragment of ApoB-100 or an immunogenically active portion thereof, wherein the one or more immunogenic fragments or immunogenically active portion thereof are associated to atherosclerosis reduction.

2. The method of claim 1 , wherein the one or more immunogenic fragments comprises one or more peptides each comprising one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, SEQ ID NO:25, , SEQ ID NO:45, SEQ ID NO:74SEQ ID NO:99, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 129, SEQ ID NO: 143, SEQ ID NO: 148, , SEQ ID NO:210, and SEQ ID NO:301.

3. The method of claim 1 , wherein the one or more immunogenic fragments comprises one or more peptides each comprising one of SEQ ID NO:2, SEQ ID NO: 11, , SEQ ID NO: 45, SEQ ID NO: 74, SEQ ID NO: 102, SEQ ID NO: 148, SEQ ID NO: 162, and SEQ ID NO:210.

4. The method of claim 1, wherein the one or more immunogenic fragments comprises a peptide having SEQ ID NO: 143 and a peptide having SEQ ID NO: 210.

5. The method of claim 1, wherein the one or more immunogenic fragments comprises a peptide having SEQ ID NO: 11, a peptide having SEQ ID NO: 25 and a peptide having SEQ ID NO: 74.

6. The method of any one of claims 1 to 4, wherein the one or more immunogenic fragments comprises a peptide having SEQ ID NO: 2.

7. The method of any one of claims 1 to 5, wherein the one or more immunogenic fragments comprise a peptide having SEQ ID NO: 45.

8. The method of any one of claims 1 to 6, wherein the one or more immunogenic fragments comprise a peptide having SEQ ID NO: 210.

9. The method of any one of claims 1 to 8, wherein the individual is a human.

10. The method of any one of claims 1 to 9, wherein the administering is performed by administering a dosage of at least 1 mg between 1 and 3 times.

11. A method to treat and/or prevent an aneurysm and/or a condition associated thereto in an individual, the method comprising

administering to the individual an effective amount of an activated CD8(+) T cells specific for an immunogenic fragment of ApoB-100 or an immunogenically active portion thereof, wherein the one or more immunogenic fragments or immunogenically active portion thereof are associated to atherosclerosis reduction.

12. The method of claim 11, wherein the one or more immunogenic fragments comprises one or more peptides each comprising one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, SEQ ID NO:25, SEQ ID NO:45SEQ ID NO:74, SEQ ID NO:99, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 129, SEQ ID NO: 143, SEQ ID NO: 148, SEQ ID NO:210, and SEQ ID NO:301.

13. The method of claims 12, wherein the one or more immunogenic comprises one or more peptides each comprising one of SEQ ID NO: 2, SEQ ID NO: 11, SEQ ID NO: 45, SEQ ID NO: 74, SEQ ID NO: 102, SEQ ID NO: 148, SEQ ID NO: 162, and SEQ ID NO:210.

14. The method of any one of claims 11 to 13, wherein the one or more immunogenic fragments comprises a peptide having SEQ ID NO: 143 and a peptide having SEQ ID NO: 210

15. The method of any one of claims 11 to 13, wherein the one or more immunogenic fragments comprises a peptide having SEQ ID NO: 11, a peptide having SEQ ID NO: 25 and a peptide having SEQ ID NO: 74.

16. The method of any one of claims 11 to 15, wherein the one or more immunogenic fragments comprises a peptide having SEQ ID NO: 2.

17. The method of any one of claims 11 to 16, wherein the one or more immunogenic fragments comprise a peptide having SEQ ID NO: 45.

18. The method of any one of claims 11 to 17, wherein the one or more immunogenic fragments comprise a peptide having SEQ ID NO: 210.

19. The method of any one of claims 11 to 18, wherein the effective amount is between about 500,000 and about 2,000,000 CD8(+) T cells.

20. The method of any one of claims 11 to 19, wherein the administering is performed by administering about 1,000,000 cells to the individual.

21. The method of any one of claims 11 to 20, wherein the method further comprises administering an effective amount of one or more enhancer of CD8(+) T cells.

22. The method of any one of claims 11 to 21 the method further comprising administering an immunogenic fragment of apoB-100 or an immunogenically active portion thereof.

23. The method of any one of claims 11 to 22, wherein the activated CD8(+) T cells specific for the immunogenic fragment of ApoBlOO are obtainable by

contacting a CD8(+) T cells with one or more peptides selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:302 or an immunogenically active portion thereof for a time and under condition to activate the CD8(+) T cell, the activated CD8(+) T cell specific for the one or more peptides or the immunogenically active portion thereof.

24. A system to treat and/or prevent an aneurysm and/or a condition associated thereto in an individual, the system comprising at least two of

one or more of a CD8(+) T cell specific for an immunogenic fragment of ApoB-100 or an immunogenically active portion thereof; and

one or more enhancers of the CD8(+ )T cell

25. A system to treat and/or prevent an aneurysm and/or a condition associated thereto in an individual, the system comprising at least two of

one or more immunogenic fragments of ApoB-100 or an immunogenically active portion thereof and CD8(+) T cell; and

one or more of a CD8(+) T cell specific for an immunogenic fragment of ApoB-100 or an immunogenically active portion thereof.

26. The system of claim 25, further comprising one or more enhancers of the CD8(+) T cell.